ID

39118

Description

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms; ODM derived from: https://clinicaltrials.gov/show/NCT01194440

Link

https://clinicaltrials.gov/show/NCT01194440

Keywords

Versions (1)
  1. 12/2/19 12/2/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

December 2, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Ductal Carcinoma in Situ NCT01194440

English

Eligibility Ductal Carcinoma in Situ NCT01194440

1 forms  
Criteria
Description

Criteria

patients with histologically proven dcis or stage i-iii invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive by immunohistochemical staining who are considering aromatase inhibitor therapy; women may receive the ai on this study as initial adjuvant hormonal treatment or following tamoxifen; patients must have completed any adjuvant chemotherapy; patients may have received preoperative chemotherapy
Description

DCIS | Invasive carcinoma of breast Estrogen receptor positive TNM Breast tumor staging | Invasive carcinoma of breast Progesterone receptor positive TNM Breast tumor staging | Immunohistochemistry | Aromatase Inhibitors considering | Tamoxifen | Adjuvant Chemotherapy Completed | Preoperative Chemotherapy

Data type

boolean

Alias
UMLS CUI [1]
C0007124
UMLS CUI [2,1]
C0853879
UMLS CUI [2,2]
C0279754
UMLS CUI [2,3]
C0474926
UMLS CUI [3,1]
C0853879
UMLS CUI [3,2]
C0279759
UMLS CUI [3,3]
C0474926
UMLS CUI [4]
C0021044
UMLS CUI [5,1]
C0593802
UMLS CUI [5,2]
C0750591
UMLS CUI [6]
C0039286
UMLS CUI [7,1]
C0085533
UMLS CUI [7,2]
C0205197
UMLS CUI [8]
C2347669
postmenopausal status, defined as: >= 60 years of age; or < 60 years of age and amenorrheic for >= 12 months prior to day 1 if intact uterus/ovaries; or < 60 years of age, and the last menstrual period 6-12 months prior to day 1, if intact uterus/ovaries and meets biochemical criteria for menopause (fsh and estradiol within institutional standards for postmenopausal status); or < 60 years of age, without a uterus, and meets biochemical criteria for menopause (fsh and estradiol within institutional standards for postmenopausal status); or < 60 years of age and history of bilateral oophorectomy; or prior radiation castration with amenorrhea for at least 6 months; < 60 years of age and taking medication designed to suppress ovarian function and meets biochemical criteria for menopause (estradiol levels within institutional standards for postmenopausal status; women would have had to be taking the drug for at least 30 days prior to day 1)
Description

Postmenopausal state | Age | Amenorrhea | Uterus Intact | Both ovaries Intact | Follicle stimulating hormone measurement | Estradiol measurement | Uterus Absent | Bilateral oophorectomy | Radiation castration | Pharmaceutical Preparations Suppressing Ovarian function

Data type

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0001779
UMLS CUI [3]
C0002453
UMLS CUI [4,1]
C0042149
UMLS CUI [4,2]
C0205266
UMLS CUI [5,1]
C0227898
UMLS CUI [5,2]
C0205266
UMLS CUI [6]
C0202022
UMLS CUI [7]
C0337434
UMLS CUI [8,1]
C0042149
UMLS CUI [8,2]
C0332197
UMLS CUI [9]
C0278321
UMLS CUI [10]
C0877129
UMLS CUI [11,1]
C0013227
UMLS CUI [11,2]
C1260953
UMLS CUI [11,3]
C0678879
ecog performance status 0-2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
patient is aware of the nature of her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form
Description

Comprehension Study Protocol | Informed Consent

Data type

boolean

Alias
UMLS CUI [1,1]
C0162340
UMLS CUI [1,2]
C2348563
UMLS CUI [2]
C0021430
exclusion
Description

Exclusion Criteria

Data type

boolean

Alias
UMLS CUI [1]
C0680251
concurrent use of hormone replacement therapy
Description

Hormone replacement therapy

Data type

boolean

Alias
UMLS CUI [1]
C0282402
concurrent use of tamoxifen; patients taking tamoxifen must discontinue the drug prior to first dose of zoledronic acid
Description

Tamoxifen | Tamoxifen To be stopped

Data type

boolean

Alias
UMLS CUI [1]
C0039286
UMLS CUI [2,1]
C0039286
UMLS CUI [2,2]
C1272691
concurrent use of other selective estrogen receptor modulator (serm) such as raloxifene
Description

Selective Estrogen Receptor Modulators | Raloxifene

Data type

boolean

Alias
UMLS CUI [1]
C0732611
UMLS CUI [2]
C0244404
concurrent consumption of soy supplements; routine dietary consumption of soy containing foods will be permitted
Description

Consumption Soy Supplements

Data type

boolean

Alias
UMLS CUI [1,1]
C0009830
UMLS CUI [1,2]
C0037733
UMLS CUI [1,3]
C0242295
prior use of an aromatase inhibitor in any setting
Description

Aromatase Inhibitors Previous

Data type

boolean

Alias
UMLS CUI [1,1]
C0593802
UMLS CUI [1,2]
C0205156
current bisphosphonate use (oral or intravenous); prior bisphosphonate users would be eligible as long as the use was > 1 month ago for oral bisphosphonates and/or > 12 months ago for intravenous bisphosphonates, prior to starting study treatment
Description

Diphosphonates Oral | Diphosphonates Intravenous

Data type

boolean

Alias
UMLS CUI [1,1]
C0012544
UMLS CUI [1,2]
C1527415
UMLS CUI [2,1]
C0012544
UMLS CUI [2,2]
C1522726
moderate to severe renal impairment (serum creatinine greater than 2 mg/dl or creatinine clearance less than 50 ml/min)
Description

Renal Insufficiency Moderate | Renal Insufficiency Severe | Creatinine measurement, serum | Creatinine clearance measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C1565489
UMLS CUI [1,2]
C0205081
UMLS CUI [2,1]
C1565489
UMLS CUI [2,2]
C0205082
UMLS CUI [3]
C0201976
UMLS CUI [4]
C0373595
hypersensitivity to letrozole or zoledronic acid or any of its excipients
Description

Hypersensitivity Letrozole | Zoledronic acid allergy | Hypersensitivity Letrozole Excipient | Hypersensitivity Zoledronic acid Excipient

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0246421
UMLS CUI [2]
C4544924
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0246421
UMLS CUI [3,3]
C0015237
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0257685
UMLS CUI [4,3]
C0015237
concomitant treatment with oral or intravenous corticosteroids
Description

Adrenal Cortex Hormones Oral | Adrenal Cortex Hormones Intravenous

Data type

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C1527415
UMLS CUI [2,1]
C0001617
UMLS CUI [2,2]
C1522726
current active dental problems including infection or the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (onj), of exposed bone in the mouth, or of slow healing after dental procedures
Description

Tooth problem | Infection of tooth | infection jaw | Maxilla infection | Lower jaw bone infection | Dental trauma | Fixture Trauma | Osteonecrosis of jaw | Exposed bone in jaw | Healing Slow | Status post Dental Procedure

Data type

boolean

Alias
UMLS CUI [1]
C0576962
UMLS CUI [2]
C0877046
UMLS CUI [3]
C1400570
UMLS CUI [4]
C1400602
UMLS CUI [5]
C1290708
UMLS CUI [6]
C1301685
UMLS CUI [7,1]
C3879289
UMLS CUI [7,2]
C3714660
UMLS CUI [8]
C2711248
UMLS CUI [9]
C3160827
UMLS CUI [10,1]
C0043240
UMLS CUI [10,2]
C0439834
UMLS CUI [11,1]
C0231290
UMLS CUI [11,2]
C0011331
recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)
Description

Dental surgical procedure | Dental surgical procedure Planned | Jaw Surgery | Jaw Surgery Planned | Tooth Extraction | Dental Implants

Data type

boolean

Alias
UMLS CUI [1]
C0204324
UMLS CUI [2,1]
C0204324
UMLS CUI [2,2]
C1301732
UMLS CUI [3]
C0407713
UMLS CUI [4,1]
C0407713
UMLS CUI [4,2]
C1301732
UMLS CUI [5]
C0040440
UMLS CUI [6]
C0376511
Back to the top of the page

Similar models

Eligibility Ductal Carcinoma in Situ NCT01194440

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
DCIS | Invasive carcinoma of breast Estrogen receptor positive TNM Breast tumor staging | Invasive carcinoma of breast Progesterone receptor positive TNM Breast tumor staging | Immunohistochemistry | Aromatase Inhibitors considering | Tamoxifen | Adjuvant Chemotherapy Completed | Preoperative Chemotherapy
Item
patients with histologically proven dcis or stage i-iii invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive by immunohistochemical staining who are considering aromatase inhibitor therapy; women may receive the ai on this study as initial adjuvant hormonal treatment or following tamoxifen; patients must have completed any adjuvant chemotherapy; patients may have received preoperative chemotherapy
boolean
C0007124 (UMLS CUI [1])
C0853879 (UMLS CUI [2,1])
C0279754 (UMLS CUI [2,2])
C0474926 (UMLS CUI [2,3])
C0853879 (UMLS CUI [3,1])
C0279759 (UMLS CUI [3,2])
C0474926 (UMLS CUI [3,3])
C0021044 (UMLS CUI [4])
C0593802 (UMLS CUI [5,1])
C0750591 (UMLS CUI [5,2])
C0039286 (UMLS CUI [6])
C0085533 (UMLS CUI [7,1])
C0205197 (UMLS CUI [7,2])
C2347669 (UMLS CUI [8])
Postmenopausal state | Age | Amenorrhea | Uterus Intact | Both ovaries Intact | Follicle stimulating hormone measurement | Estradiol measurement | Uterus Absent | Bilateral oophorectomy | Radiation castration | Pharmaceutical Preparations Suppressing Ovarian function
Item
postmenopausal status, defined as: >= 60 years of age; or < 60 years of age and amenorrheic for >= 12 months prior to day 1 if intact uterus/ovaries; or < 60 years of age, and the last menstrual period 6-12 months prior to day 1, if intact uterus/ovaries and meets biochemical criteria for menopause (fsh and estradiol within institutional standards for postmenopausal status); or < 60 years of age, without a uterus, and meets biochemical criteria for menopause (fsh and estradiol within institutional standards for postmenopausal status); or < 60 years of age and history of bilateral oophorectomy; or prior radiation castration with amenorrhea for at least 6 months; < 60 years of age and taking medication designed to suppress ovarian function and meets biochemical criteria for menopause (estradiol levels within institutional standards for postmenopausal status; women would have had to be taking the drug for at least 30 days prior to day 1)
boolean
C0232970 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0002453 (UMLS CUI [3])
C0042149 (UMLS CUI [4,1])
C0205266 (UMLS CUI [4,2])
C0227898 (UMLS CUI [5,1])
C0205266 (UMLS CUI [5,2])
C0202022 (UMLS CUI [6])
C0337434 (UMLS CUI [7])
C0042149 (UMLS CUI [8,1])
C0332197 (UMLS CUI [8,2])
C0278321 (UMLS CUI [9])
C0877129 (UMLS CUI [10])
C0013227 (UMLS CUI [11,1])
C1260953 (UMLS CUI [11,2])
C0678879 (UMLS CUI [11,3])
ECOG performance status
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Comprehension Study Protocol | Informed Consent
Item
patient is aware of the nature of her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form
boolean
C0162340 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2])
Exclusion Criteria
Item
exclusion
boolean
C0680251 (UMLS CUI [1])
Hormone replacement therapy
Item
concurrent use of hormone replacement therapy
boolean
C0282402 (UMLS CUI [1])
Tamoxifen | Tamoxifen To be stopped
Item
concurrent use of tamoxifen; patients taking tamoxifen must discontinue the drug prior to first dose of zoledronic acid
boolean
C0039286 (UMLS CUI [1])
C0039286 (UMLS CUI [2,1])
C1272691 (UMLS CUI [2,2])
Selective Estrogen Receptor Modulators | Raloxifene
Item
concurrent use of other selective estrogen receptor modulator (serm) such as raloxifene
boolean
C0732611 (UMLS CUI [1])
C0244404 (UMLS CUI [2])
Consumption Soy Supplements
Item
concurrent consumption of soy supplements; routine dietary consumption of soy containing foods will be permitted
boolean
C0009830 (UMLS CUI [1,1])
C0037733 (UMLS CUI [1,2])
C0242295 (UMLS CUI [1,3])
Aromatase Inhibitors Previous
Item
prior use of an aromatase inhibitor in any setting
boolean
C0593802 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
Diphosphonates Oral | Diphosphonates Intravenous
Item
current bisphosphonate use (oral or intravenous); prior bisphosphonate users would be eligible as long as the use was > 1 month ago for oral bisphosphonates and/or > 12 months ago for intravenous bisphosphonates, prior to starting study treatment
boolean
C0012544 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0012544 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
Renal Insufficiency Moderate | Renal Insufficiency Severe | Creatinine measurement, serum | Creatinine clearance measurement
Item
moderate to severe renal impairment (serum creatinine greater than 2 mg/dl or creatinine clearance less than 50 ml/min)
boolean
C1565489 (UMLS CUI [1,1])
C0205081 (UMLS CUI [1,2])
C1565489 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0201976 (UMLS CUI [3])
C0373595 (UMLS CUI [4])
Hypersensitivity Letrozole | Zoledronic acid allergy | Hypersensitivity Letrozole Excipient | Hypersensitivity Zoledronic acid Excipient
Item
hypersensitivity to letrozole or zoledronic acid or any of its excipients
boolean
C0020517 (UMLS CUI [1,1])
C0246421 (UMLS CUI [1,2])
C4544924 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C0246421 (UMLS CUI [3,2])
C0015237 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C0257685 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
Adrenal Cortex Hormones Oral | Adrenal Cortex Hormones Intravenous
Item
concomitant treatment with oral or intravenous corticosteroids
boolean
C0001617 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0001617 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
Tooth problem | Infection of tooth | infection jaw | Maxilla infection | Lower jaw bone infection | Dental trauma | Fixture Trauma | Osteonecrosis of jaw | Exposed bone in jaw | Healing Slow | Status post Dental Procedure
Item
current active dental problems including infection or the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (onj), of exposed bone in the mouth, or of slow healing after dental procedures
boolean
C0576962 (UMLS CUI [1])
C0877046 (UMLS CUI [2])
C1400570 (UMLS CUI [3])
C1400602 (UMLS CUI [4])
C1290708 (UMLS CUI [5])
C1301685 (UMLS CUI [6])
C3879289 (UMLS CUI [7,1])
C3714660 (UMLS CUI [7,2])
C2711248 (UMLS CUI [8])
C3160827 (UMLS CUI [9])
C0043240 (UMLS CUI [10,1])
C0439834 (UMLS CUI [10,2])
C0231290 (UMLS CUI [11,1])
C0011331 (UMLS CUI [11,2])
Dental surgical procedure | Dental surgical procedure Planned | Jaw Surgery | Jaw Surgery Planned | Tooth Extraction | Dental Implants
Item
recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)
boolean
C0204324 (UMLS CUI [1])
C0204324 (UMLS CUI [2,1])
C1301732 (UMLS CUI [2,2])
C0407713 (UMLS CUI [3])
C0407713 (UMLS CUI [4,1])
C1301732 (UMLS CUI [4,2])
C0040440 (UMLS CUI [5])
C0376511 (UMLS CUI [6])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial